BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 3855284)

  • 1. Cytotoxic effects of folate antagonists against methotrexate-resistant human leukemic lymphoblast CCRF-CEM cell lines.
    Mini E; Moroson BA; Franco CT; Bertino JR
    Cancer Res; 1985 Jan; 45(1):325-30. PubMed ID: 3855284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patterns of cross-resistance to the antifolate drugs trimetrexate, metoprine, homofolate, and CB3717 in human lymphoma and osteosarcoma cells resistant to methotrexate.
    Diddens H; Niethammer D; Jackson RC
    Cancer Res; 1983 Nov; 43(11):5286-92. PubMed ID: 6225514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytotoxicity of trimetrexate against antifolate-resistant human T-cell leukemia cell lines developed in oxidized or reduced folate.
    Miyachi H; Takemura Y; Kobayashi H; Ando Y
    Jpn J Cancer Res; 1997 Sep; 88(9):900-6. PubMed ID: 9369939
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular and karyological analysis of methotrexate-resistant and -sensitive human leukemic CCRF-CEM cells.
    Mini E; Srimatkandada S; Medina WD; Moroson BA; Carman MD; Bertino JR
    Cancer Res; 1985 Jan; 45(1):317-24. PubMed ID: 3855283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Establishment of methotrexate-resistant human acute lymphoblastic leukemia cells in culture and effects of folate antagonists.
    Ohnoshi T; Ohnuma T; Takahashi I; Scanlon K; Kamen BA; Holland JF
    Cancer Res; 1982 May; 42(5):1655-60. PubMed ID: 6978176
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multifactorial resistance to 5,10-dideazatetrahydrofolic acid in cell lines derived from human lymphoblastic leukemia CCRF-CEM.
    Pizzorno G; Moroson BA; Cashmore AR; Russello O; Mayer JR; Galivan J; Bunni MA; Priest DG; Beardsley GP
    Cancer Res; 1995 Feb; 55(3):566-73. PubMed ID: 7834626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. N10-propargyl-5,8-dideazafolic acid (CB3717): inhibitory effects on human leukemia cell lines resistant to methotrexate or trimetrexate.
    Takemura Y; Ohnuma T
    Mt Sinai J Med; 1992 Oct; 59(5):419-24. PubMed ID: 1435841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impaired polyglutamylation of methotrexate as a cause of resistance in CCRF-CEM cells after short-term, high-dose treatment with this drug.
    Pizzorno G; Mini E; Coronnello M; McGuire JJ; Moroson BA; Cashmore AR; Dreyer RN; Lin JT; Mazzei T; Periti P
    Cancer Res; 1988 Apr; 48(8):2149-55. PubMed ID: 2450647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of a membrane-associated folate-binding protein in human leukemic CCRF-CEM cells with transport-related methotrexate resistance.
    Jansen G; Westerhof GR; Kathmann I; Rademaker BC; Rijksen G; Schornagel JH
    Cancer Res; 1989 May; 49(9):2455-9. PubMed ID: 2706633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thymidylate synthase as a target for growth inhibition in methotrexate-sensitive and -resistant human head and neck cancer and leukemia cell lines.
    McGuire JJ; Magee KJ; Russell CA; Canestrari JM
    Oncol Res; 1997; 9(3):139-47. PubMed ID: 9220499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biochemical studies on PT523, a potent nonpolyglutamatable antifolate, in cultured cells.
    Rhee MS; Galivan J; Wright JE; Rosowsky A
    Mol Pharmacol; 1994 Apr; 45(4):783-91. PubMed ID: 7514264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumor activity of antifolate inhibitors of thymidylate and purine synthesis in human soft tissue sarcoma cell lines with intrinsic resistance to methotrexate.
    Li WW; Tong WP; Bertino JR
    Clin Cancer Res; 1995 Jun; 1(6):631-6. PubMed ID: 9816025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elevation of dihydrofolate reductase, thymidylate synthetase, and thymidine kinase in cultured mammalian cells after exposure to folate antagonists.
    Chello PL; McQueen CA; DeAngelis LM; Bertino JR
    Cancer Res; 1976 Jul; 36(7 PT 1):2442-9. PubMed ID: 1277151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of polyglutamation on sensitivity to raltitrexed and methotrexate in relation to drug-induced inhibition of de novo thymidylate and purine biosynthesis in CCRF-CEM cell lines.
    Barnes MJ; Estlin EJ; Taylor GA; Aherne GW; Hardcastle A; McGuire JJ; Calvete JA; Lunec J; Pearson AD; Newell DR
    Clin Cancer Res; 1999 Sep; 5(9):2548-58. PubMed ID: 10499632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancement of trimetrexate cytotoxicity in vitro and in vivo by carboxypeptidase G2.
    Romanini A; Sobrero AF; Chou TC; Sherwood RF; Bertino JR
    Cancer Res; 1989 Nov; 49(21):6019-23. PubMed ID: 2529027
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dihydrofolate reductase binding and cellular uptake of nonpolyglutamatable antifolates: correlates of cytotoxicity toward methotrexate-sensitive and -resistant human head and neck squamous carcinoma cells.
    Chen G; Wright JE; Rosowsky A
    Mol Pharmacol; 1995 Oct; 48(4):758-65. PubMed ID: 7476904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiple membrane transport systems for the uptake of folate-based thymidylate synthase inhibitors.
    Jansen G; Schornagel JH; Westerhof GR; Rijksen G; Newell DR; Jackman AL
    Cancer Res; 1990 Dec; 50(23):7544-8. PubMed ID: 2253202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biochemical and growth inhibition studies of methotrexate and aminopterin analogues containing a tetrazole ring in place of the gamma-carboxyl group.
    McGuire JJ; Russell CA; Bolanowska WE; Freitag CM; Jones CS; Kalman TI
    Cancer Res; 1990 Mar; 50(6):1726-31. PubMed ID: 2306727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel 6,5-fused ring heterocyclic antifolates: biochemical and biological characterization.
    McGuire JJ; Bergoltz VV; Heitzman KJ; Haile WH; Russell CA; Bolanowska WE; Kotake Y; Haneda T; Nomura H
    Cancer Res; 1994 May; 54(10):2673-9. PubMed ID: 8168096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 5-amino-4-imidazolecarboxamide riboside potentiates both transport of reduced folates and antifolates by the human reduced folate carrier and their subsequent metabolism.
    McGuire JJ; Haile WH; Yeh CC
    Cancer Res; 2006 Apr; 66(7):3836-44. PubMed ID: 16585211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.